Ingelheim, Germany, September 29, 2026
Boehringer Ingelheim announced that investments in sustainability-related programs and health partnerships are projected to reach €500 million by the end of 2026, covering initiatives designed to strengthen healthcare systems and improve the lives of people, animals and communities. The company shared the investment outlook during its Making More Health Together Convention in Ingelheim, which brought together more than 400 health entrepreneurs, investors and healthcare-system partners. The program represents a long-term approach to combining pharmaceutical-sector expertise, social investment and partnerships to address healthcare challenges, including infectious diseases, antimicrobial resistance (AMR), healthcare access and diagnostics.
Boehringer Ingelheim Expands Health Partnerships
The projected €500 million investment includes spending accumulated over the past five years together with the forecast for 2026. A major component is the Boehringer Ingelheim Social Engagement Fund (BISE), a €50 million initiative created to support social enterprises developing solutions for healthcare systems and underserved communities. The company said 80% of the fund has already been committed, supporting 27 social start-ups across Africa and Latin America. These organizations are working in areas including primary healthcare, health insurance, diagnostics, telehealth, mobile clinics and last-mile medicine delivery. The BISE portfolio includes 24 organizations in Africa and three in Latin America, while another 38 companies have received support to prepare for potential funding. Boehringer Ingelheim said the portfolio is projected to exceed its original 2021 ambition of improving the lives of 50 million people by 2030. The fund combines impact-focused financing with business expertise, technical assistance and access to professional networks, providing social entrepreneurs with resources intended to help them scale healthcare solutions beyond individual communities.
€125 Million Supports AMR and Infectious Disease
Another significant element of Boehringer Ingelheim’s strategy is its investment in efforts addressing antimicrobial resistance and emerging infectious diseases. The company said it has provided more than €125 million since 2021 through partnerships focused on these areas. AMR remains a major challenge for healthcare systems because resistance can reduce the effectiveness of existing antibiotics and create demand for new approaches to prevention, diagnosis and treatment. Boehringer Ingelheim said it is strengthening this commitment by establishing additional internal research capabilities in antimicrobial resistance. The company plans to combine its own scientific expertise with collaborations involving academia, biotechnology companies and industry partners. This approach is intended to support the development of new solutions for infectious diseases and AMR, areas where the company notes that commercial incentives have contributed to a relatively limited antibiotic development pipeline.
Advertisement
Social Innovation Supports Global Healthcare Access
The company’s social-health partnerships include initiatives designed to improve access to healthcare in underserved populations. Zuri Health, for example, provides primary care through telemedicine and mobile clinics in Kenya and has reached more than six million people, according to Boehringer Ingelheim. ThinkMD provides an AI-supported clinical decision tool for frontline health workers and is operating in seven countries, with more than three million people reached to date. In Romania, Boehringer works with Caravana cu Medici to bring screening and diagnostic services to rural communities. Boehringer Ingelheim is also preparing the next phase of its Social Engagement Fund, with approximately 50% to 75% of financing expected to be repaid from 2032 onward. The company plans to reinvest those returns into a new generation of health entrepreneurs, with the goal of developing the fund into a more self-sustaining impact-financing platform. The company also plans to connect the fund with wider health initiatives, including CRM Patient Africa and the Angels Initiative, giving supported entrepreneurs greater access to clinical expertise, distribution networks and policymakers.
The announcement demonstrates how a major biopharmaceutical company is combining sustainability investment, healthcare partnerships and scientific capabilities to address health-system challenges. With projected investments reaching €500 million in 2026, more than €125 million directed toward infectious diseases and AMR partnerships, and continued support for social healthcare enterprises, Boehringer Ingelheim is expanding its role beyond traditional pharmaceutical research and development into health-system strengthening, social innovation and global health initiatives.
Source: Boehringer Ingelheim press release
